NO20001399D0 - Kombinasjon av en 5-HT gjenopptaksinhibitor og en h5-HT1B antagonist eller partiell agonist - Google Patents

Kombinasjon av en 5-HT gjenopptaksinhibitor og en h5-HT1B antagonist eller partiell agonist

Info

Publication number
NO20001399D0
NO20001399D0 NO20001399A NO20001399A NO20001399D0 NO 20001399 D0 NO20001399 D0 NO 20001399D0 NO 20001399 A NO20001399 A NO 20001399A NO 20001399 A NO20001399 A NO 20001399A NO 20001399 D0 NO20001399 D0 NO 20001399D0
Authority
NO
Norway
Prior art keywords
combination
reuptake inhibitor
partial agonist
ht1b antagonist
ht1b
Prior art date
Application number
NO20001399A
Other languages
English (en)
Other versions
NO20001399L (no
Inventor
Stefan Berg
Svante Ross
Seth-Olov Thorberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20001399D0 publication Critical patent/NO20001399D0/no
Publication of NO20001399L publication Critical patent/NO20001399L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
  • Replacement Of Web Rolls (AREA)
NO20001399A 1997-09-18 2000-03-17 Kombinasjon av en 5-HT gjenopptaksinhibitor og en h5-HT1B antagonist eller partiell agonist NO20001399L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001601 WO1999013877A1 (en) 1997-09-18 1998-09-09 A COMBINATION OF A 5-HT REUPTAKE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST

Publications (2)

Publication Number Publication Date
NO20001399D0 true NO20001399D0 (no) 2000-03-17
NO20001399L NO20001399L (no) 2000-05-10

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001399A NO20001399L (no) 1997-09-18 2000-03-17 Kombinasjon av en 5-HT gjenopptaksinhibitor og en h5-HT1B antagonist eller partiell agonist

Country Status (30)

Country Link
US (1) US6159971A (no)
EP (1) EP1014985B1 (no)
JP (1) JP2001516718A (no)
KR (1) KR20010024076A (no)
CN (1) CN1195519C (no)
AR (1) AR015448A1 (no)
AT (1) ATE240733T1 (no)
AU (1) AU752722B2 (no)
BR (1) BR9812088A (no)
CA (1) CA2302382A1 (no)
DE (1) DE69814882T2 (no)
DK (1) DK1014985T3 (no)
EE (1) EE04141B1 (no)
ES (1) ES2200370T3 (no)
HK (1) HK1032739A1 (no)
HU (1) HUP0200602A3 (no)
IL (1) IL134776A0 (no)
IS (1) IS5406A (no)
MY (1) MY116280A (no)
NO (1) NO20001399L (no)
NZ (1) NZ503171A (no)
PL (1) PL339371A1 (no)
PT (1) PT1014985E (no)
RU (1) RU2214824C2 (no)
SE (1) SE9703375D0 (no)
SK (1) SK2852000A3 (no)
TR (1) TR200000727T2 (no)
TW (1) TW589183B (no)
WO (1) WO1999013877A1 (no)
ZA (1) ZA987817B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (en) * 2001-02-21 2002-08-29 Sankyo Company, Limited Chromene derivatives
EA200301195A1 (ru) * 2001-05-01 2004-04-29 Х. Лундбекк А/С Применение энантиомерно чистого эсциталопрама
JP5080716B2 (ja) * 2001-07-20 2012-11-21 サイコジェニックス・インコーポレーテッド 注意欠陥・多動性障害の治療
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
WO2006091725A1 (en) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Treatment of anhedonia
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
JP2009513604A (ja) 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
AR062321A1 (es) 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives

Also Published As

Publication number Publication date
EE04141B1 (et) 2003-10-15
EP1014985B1 (en) 2003-05-21
HUP0200602A3 (en) 2003-04-28
BR9812088A (pt) 2000-09-26
EE200000141A (et) 2001-02-15
NO20001399L (no) 2000-05-10
IL134776A0 (en) 2001-04-30
HUP0200602A2 (hu) 2002-07-29
CN1278729A (zh) 2001-01-03
TW589183B (en) 2004-06-01
AR015448A1 (es) 2001-05-02
ES2200370T3 (es) 2004-03-01
CA2302382A1 (en) 1999-03-25
ATE240733T1 (de) 2003-06-15
KR20010024076A (ko) 2001-03-26
US6159971A (en) 2000-12-12
ZA987817B (en) 1999-03-18
NZ503171A (en) 2002-02-01
SK2852000A3 (en) 2000-09-12
JP2001516718A (ja) 2001-10-02
PT1014985E (pt) 2003-10-31
PL339371A1 (en) 2000-12-18
RU2214824C2 (ru) 2003-10-27
SE9703375D0 (sv) 1997-09-18
WO1999013877A1 (en) 1999-03-25
CN1195519C (zh) 2005-04-06
MY116280A (en) 2003-12-31
DE69814882D1 (de) 2003-06-26
TR200000727T2 (tr) 2000-09-21
HK1032739A1 (en) 2001-08-03
DE69814882T2 (de) 2004-05-19
AU752722B2 (en) 2002-09-26
AU9193098A (en) 1999-04-05
DK1014985T3 (da) 2003-09-15
IS5406A (is) 2000-03-15
EP1014985A1 (en) 2000-07-05

Similar Documents

Publication Publication Date Title
NO20001399L (no) Kombinasjon av en 5-HT gjenopptaksinhibitor og en h5-HT1B antagonist eller partiell agonist
HUP0203586A3 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
NO983278L (no) System for inspeksjon og evaluering av utstyr, system for administrering av
EE03553B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon selektiivse 5-HT1A antagonistiga
DK0813873T3 (da) Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere
EP1009415A4 (en) INHIBITORS OF $ g (b) -LACTAMASES AND THEIR USES
MX220980B (en) Cementing compositions and use of such compositions for cementing oil wells or the like
IL134775A0 (en) A COMBINATION OF A MONOAMINE OXIDASE INHIBITOR AND A h5-HT1B ANTAGONIST OR PARTIAL AGONIST
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
NO991374L (no) Marint stiger°r og fremgangsmÕte for bruk
NO20006626D0 (no) Beleggingsmiddel og anvendelse herav
DZ2556A1 (fr) Compositions nouvelles d'inhibiteur sélectif de réabsorption de sérotonine et d'un beta-bloquant.
NO20001398L (no) Kombinasjon av en 5-HT1A antagonist og en selektiv h5-HT1B antagonist eller partial antagonist
SI1014985T1 (en) A combination of a 5-ht reuptake inhibitor and a h5-ht 1b antagonist or partial agonist
SI1237553T1 (sl) Kombinacija inhibitorja ponovnega navzema serotonina in antagonista 5-ht 2c?, inverznega agonista ali delnega agonista
IT1294730B1 (it) Procedimento per la fabbricazione a macchina di un libro e simili
SI1021183T1 (en) A COMBINATION OF A SELECTIVE 5-HT1A ANTAGONIST AND A SELECTIVE h5-HT1B ANTAGONIST OR PARTIAL AGONIST
AU3148500A (en) Scale and corrosion inhibitor
IT1313754B1 (it) Pistola sparalamelle e/o groppini particolarmente utilizata percornici e simili
IT1303127B1 (it) Installazione depuratrice di residui porcini e simili.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application